Showing results (141-150 of 162) with videos related to

Sort By:
Pageof 17
International Journal of Cancer|June 11, 2015
Clostridium perfringens enterotoxin C-terminal domain labeled to fluorescent dyes for in vivo visualization of micrometastatic chemotherapy-resistant ovarian cancerEmiliano Cocco, Erik M Shapiro, Sara Gasparrini, et al.
Oncotarget|February 22, 2020
Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomasSalvatore Lopez, Emanuele Perrone, Stefania Bellone, et al.
Gynecologic Oncology|December 16, 2022
Ovarian and uterine carcinosarcomas are sensitive in vitro and in vivo to elimusertib, a novel ataxia-telangiectasia and Rad3-related (ATR) kinase inhibitorDiego D Manavella, Blair McNamara, Justin Harold, et al.
Molecular Cancer Therapeutics|February 15, 2018
In Vitro and In Vivo Activity of IMGN853, an Antibody-Drug Conjugate Targeting Folate Receptor Alpha Linked to DM4, in Biologically Aggressive Endometrial CancersGary Altwerger, Elena Bonazzoli, Stefania Bellone, et al.
Gynecologic Oncology|March 25, 2018
A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinomaChanhee Han, Stefania Bellone, Eric R Siegel, et al.
Cancer|April 1, 2021
Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: An individual patient data meta-analysisJessica N McAlpine, Derek S Chiu, Remi A Nout, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 1, 2020
Randomized Phase II Trial of Carboplatin-Paclitaxel Compared with Carboplatin-Paclitaxel-Trastuzumab in Advanced (Stage III-IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival AnalysisAmanda N Fader, Dana M Roque, Eric Siegel, et al.
Molecular Cancer Therapeutics|September 7, 2023
In Vivo and In Vitro Efficacy of Trastuzumab Deruxtecan in Uterine Serous CarcinomaLevent Mutlu, Diego D Manavella, Stefania Bellone, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 28, 2018
Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neuAmanda N Fader, Dana M Roque, Eric Siegel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 27, 2018
Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial CancerElena Bonazzoli, Federica Predolini, Emiliano Cocco, et al.
Pageof 17